• Inogen’s 2024 annual report flagged a return to growth, led by a sharp rebound in its business-to-business channel.
• Direct-to-consumer sales remained under pressure following salesforce reductions; the rental channel also weakened as patients shifted toward private insurance.
• Collaboration with Yuwell Medical positioned the company to enter China while adding a stationary oxygen concentrator to its portfolio.
• FDA 510(k) clearance for the Simeox airway clearance device in December set up a US commercialization push, with reimbursement work starting in Q1 2025.
• Product updates included the Rove 4 portable oxygen concentrator launch in October, supported by new features for the Inogen Connect app.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inogen Inc. published the original content used to generate this news brief on September 09, 2026, and is solely responsible for the information contained therein.